Pfizer Inc. (NYSE:PFE) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,906,565 shares of the biopharmaceutical company’s stock after selling 9,777,931 shares during the period. Legal & General Group Plc’s holdings in Pfizer were worth $979,131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Invesco Ltd. lifted its holdings in shares of Pfizer by 9.6% in the 4th quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company’s stock worth $781,524,000 after purchasing an additional 2,579,455 shares during the last quarter. Certior Financial Group LLC bought a new stake in Pfizer in the fourth quarter valued at $421,000. Wellspring Financial Advisors LLC boosted its holdings in shares of Pfizer by 49.9% during the fourth quarter. Wellspring Financial Advisors LLC now owns 16,693 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 5,560 shares during the period. Round Hill Asset Management grew its position in shares of Pfizer by 8.2% during the fourth quarter. Round Hill Asset Management now owns 152,162 shares of the biopharmaceutical company’s stock worth $4,037,000 after acquiring an additional 11,514 shares during the last quarter. Finally, Prospector Partners LLC increased its holdings in shares of Pfizer by 8.3% in the 4th quarter. Prospector Partners LLC now owns 88,555 shares of the biopharmaceutical company’s stock worth $2,349,000 after acquiring an additional 6,800 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 5.4 %

Shares of NYSE:PFE opened at $22.99 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1-year low of $22.28 and a 1-year high of $31.54. The company has a 50 day moving average price of $25.87 and a 200 day moving average price of $26.72.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm posted $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.